BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage

Clinical Cancer Research

Volumn 19, Issue 17, 2013, Pages 4589-4598

  Mar, Victoria J ^a,h,j   Wong, Stephen Q ^b   Li, Jason ^d   Scolyer, Richard A ^k,l,m   McLean, Catriona ^h   Papenfuss, Anthony T ^f,g   Tothill, Richard W ^d   Kakavand, Hojabr ^k,l,m   Mann, Graham J ^l   Thompson, John F ^k,l,m   Behren, Andreas ⁱ   Cebon, Jonathan S ⁱ   Wolfe, Rory ^j   Kelly, John W ^h   Dobrovic, Alexander ^b,f   McArthur, Grant A ^a,c,e,f  

^a Molecular Oncology Laboratory   (Australia)

^b Molecular Pathology Research and Development Laboratory   (Australia)

^c Translational Research Laboratory   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e Molecular Imaging and Therapeutic Nuclear Medicine at Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology at University of Melbourne   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^h ALFRED HOSPITAL   (Australia)

ⁱ LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^j MONASH UNIVERSITY   (Australia)

^k ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^l MELANOMA INSTITUTE AUSTRALIA   (Australia)

^m UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; NOTCH1 RECEPTOR; NUCLEAR FACTOR I; STEM CELL FACTOR;

ADULT; AGED; ARTICLE; BRAF GENE; CLINICAL ARTICLE; CONTROLLED STUDY; CUTANEOUS MELANOMA; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIT GENE; MALE; MUTANT; NF1 GENE; NOTCH1 GENE; NUCLEIC ACID BASE SUBSTITUTION; ONCOGENE N RAS; PRIORITY JOURNAL; RADIATION INJURY; SIGNAL TRANSDUCTION; SKIN DEFECT; SUNLIGHT; ULTRAVIOLET RADIATION; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; DNA DAMAGE; EXOME; FEMALE; GTP PHOSPHOHYDROLASES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; ULTRAVIOLET RAYS;

EID: 84883477049     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0398     Document Type: Article

References (49)

1. Liu W, Kelly JW, Trivett M, Murray WK, Dowling JP, Wolfe R, et al. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol 2007;127:900-5. (Pubitemid 46434654)
2. Whiteman DC, Pavan WJ, Bastian BC. The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res 2011;24:879-97.
3. Viros A, Fridlyand J, Bauer J, Lasithiotakis K, Garbe C, Pinkel D, et al. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med 2008;5:e120.
4. Broekaert SM, Roy R, Okamoto I, van den Oord J, Bauer J, Garbe C, et al. Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res 2010;23:763-70.
5. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-47. (Pubitemid 41653105)
6. Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 2012;18:3242-9.
7. Devitt B, Liu W, Salemi R, Wolfe R, Kelly J, Tzen CY, et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res 2011;24:666-72.
8. Kelleher FC, McArthur GA. Targeting NRAS in melanoma. Cancer J 2012;18:132-6.
9. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153-8. (Pubitemid 46398669)
10. Nikolaev SI, Rimoldi D, Iseli C, Valsesia A, Robyr D, Gehrig C, et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 2012;44:133-9.
11. Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 2011;43:442-6.
12. Palavalli LH, Prickett TD, Wunderlich JR, Wei X, Burrell AS, Porter-Gill P, et al. Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet 2009;41:518-20.
13. Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR, et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 2009;41:1127-32.
14. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell 2012;150:251-63.
15. Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 2012;44:1006-14.
16. Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012;485:502-6.
17. Turajlic S, Furney SJ, Lambros MB, Mitsopoulos C, Kozarewa I, Geyer FC, et al. Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res 2012;22:196-207.
18. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013;31:213-9.
19. LeBoit P, Burg G, Weedon D, Sarasin A. Skin Tumors. Pathology and genetics. Lyon, France: IARC Press; 2006.
20. Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol 2012;30:2678-83.
21. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009;25:1754-60.
22. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010;20:1297-303.
23. Picard [Internet]. [updated 2009 May 18; cited Feb 13, 2013]. Available from: http://picard.sourceforge.net/.
24. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2011;43:491-8.
25. MuTect - cancer gene analysis tools [Internet]. Cambridge, MA: Broad Institute 2012 [cited Feb 13, 2013]. Available from:https://confluence. broadinstitute.org/display/CGATools/MuTect.
26. Flicek P, Amode MR, Barrell D, Beal K, Brent S, Carvalho-Silva D, et al. Ensembl 2012. Nucleic Acids Res 2012;40:D84-90.
27. Universal protein resource (UniProt) knowledgebase [Internet] 2002-2013 [cited Feb 13, 2013]. Available from: http://www.uniprot.org/faq/30.
28. Forbes SA, Tang G, Bindal N, Bamford S, Dawson E, Cole C, et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res 2010;38:D652-7.
29. Genomics of drug sensitivity in cancer [Internet]. Cambridgeshire, UK: Wellcome Trust Sanger Institute, 2012 [cited Feb 13, 2013]. Available from: http://www.cancerrxgene.org/.
30. Vidwans SJ, Flaherty KT, Fisher DE, Tenenbaum JM, Travers MD, Shrager J. A melanoma molecular disease model. PLoS ONE 2011;6:e18257.
31. Blombery PA, Wong SQ, Hewitt CA, Dobrovic A, Maxwell EL, Juneja S, et al. Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders. Haematologica 2012;97:780-3.
32. Stark MS, Woods SL, Gartside MG, Bonazzi VF, Dutton-Regester K, Aoude LG, et al. Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat Genet 2012;44:165-9.
33. Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 2003;95:1878-90.
34. Dutton-Regester K, Irwin D, Hunt P, Aoude LG, Tembe V, Pupo GM, et al. A high-throughput panel for identifying clinically relevant mutation profiles in melanoma. Mol Cancer Ther 2012;11:888-97.
35. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 2011;3:111ra21.
36. Saldanha G, Potter L, Daforno P, Pringle JH. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies. Clin Cancer Res 2006;12:4499-505. (Pubitemid 44297798)
37. Si L, Kong Y, Xu X, Flaherty KT, Sheng X, Cui C, et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer 2012;48:94-100.
38. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med 2006;355:51-65.
39. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003;33:19-20. (Pubitemid 36068675)
40. Mar V, Roberts H, Wolfe R, English DR, Kelly JW. Nodular melanoma: a distinct clinical entity and the largest contributor to melanoma deaths in Victoria, Australia. J Am Acad Dermatol 2013;68:568-75.
41. Scolyer RA, Thompson JF. Biospecimen banking: the pathway to personalized medicine for patients with cancer. J Surg Oncol 2013;107:681-2.
42. Shaikh WR, Xiong M, Weinstock MA. The contribution of nodular subtype to melanoma mortality in the United States, 1978 to 2007. Arch Dermatol 2012;148:30-6.
43. Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, et al. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 2011;17:229-35.
44. Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008;14:6821-8.
45. Asnaghi L, Ebrahimi KB, Schreck KC, Bar EE, Coonfield ML, Bell WR, et al. Notch signaling promotes growth and invasion in uveal melanoma. Clin Cancer Res 2012;18:654-65.
46. Huang X, Wang L, Zhang H, Wang H, Zhao X, Qian G, et al. Therapeutic efficacy by targeting correction of Notch1-induced aberrants in uveal tumors. PLoS ONE 2012;7:e44301.
47. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012;483:570-5.
48. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992;356:713-5.
49. Dancey JE, Bedard PL, Onetto N, Hudson TJ. The genetic basis for cancer treatment decisions. Cell 2012;148:409-20.